Invivo anti-Mouse IL-6R Recombinant mAb

The Interleukin-6 receptor (IL-6R) is a critical component of the immune signaling pathway, functioning as either a membrane-bound protein on specific cell surfaces or as a soluble form circulating in the blood, and it plays a pivotal role in mediating the biological effects of interleukin-6 (IL-6), a pleiotropic cytokine involved in acute phase responses, inflammation, hematopoiesis, and immune regulation. Structurally, IL-6R consists of an extracellular domain that binds IL-6, a transmembrane region, and a cytoplasmic tail that lacks intrinsic kinase activity but associates with the signal-transducing subunit gp130; upon IL-6 binding to IL-6R, the complex recruits gp130, leading to its dimerization and the activation of downstream signaling cascades, primarily the JAK/STAT pathway, particularly JAK1/2 and STAT3, which subsequently regulate gene expression related to cell proliferation, differentiation, and survival. This receptor system is essential for both classical signaling, where membrane-bound IL-6R restricts IL-6 activity to cells expressing the receptor, and trans-signaling, where soluble IL-6R allows IL-6 to affect a broader range of cell types lacking membrane-bound IL-6R, thereby amplifying inflammatory responses and contributing to various pathological conditions such as chronic inflammatory diseases, autoimmune disorders, and cancer, making IL-6R a significant therapeutic target for drugs like tocilizumab, which blocks IL-6R to mitigate excessive inflammation.